Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASBP NASDAQ:CNTB NASDAQ:OVID NASDAQ:VXRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$0.45+1.4%$0.44$0.22▼$15.80$22.37M0.849.24 million shs244,413 shsCNTBConnect Biopharma$1.65+2.2%$1.88$0.51▼$2.86$91.66M-0.09117,646 shs63,282 shsOVIDOvid Therapeutics$1.22+6.6%$0.83$0.24▼$1.47$86.04M0.351.03 million shs521,643 shsVXRTVaxart$0.38-2.6%$0.38$0.26▼$0.98$87.00M1.332.74 million shs219,080 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma+8.11%+3.44%+24.04%+40.08%+44,529,900.00%CNTBConnect Biopharma+0.63%-8.52%-21.46%+60.98%+36.44%OVIDOvid Therapeutics-10.94%-8.06%+17.53%+285.27%-2.56%VXRTVaxart+6.38%+2.63%+6.56%-36.48%-58.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$0.45+1.4%$0.44$0.22▼$15.80$22.37M0.849.24 million shs244,413 shsCNTBConnect Biopharma$1.65+2.2%$1.88$0.51▼$2.86$91.66M-0.09117,646 shs63,282 shsOVIDOvid Therapeutics$1.22+6.6%$0.83$0.24▼$1.47$86.04M0.351.03 million shs521,643 shsVXRTVaxart$0.38-2.6%$0.38$0.26▼$0.98$87.00M1.332.74 million shs219,080 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma+8.11%+3.44%+24.04%+40.08%+44,529,900.00%CNTBConnect Biopharma+0.63%-8.52%-21.46%+60.98%+36.44%OVIDOvid Therapeutics-10.94%-8.06%+17.53%+285.27%-2.56%VXRTVaxart+6.38%+2.63%+6.56%-36.48%-58.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASBPAspire Biopharma 0.00N/AN/AN/ACNTBConnect Biopharma 3.50Strong Buy$7.00330.77% UpsideOVIDOvid Therapeutics 3.17Buy$3.10159.41% UpsideVXRTVaxart 3.00Buy$2.00414.80% UpsideCurrent Analyst Ratings BreakdownLatest ASBP, VXRT, OVID, and CNTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.008/8/2025OVIDOvid TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.007/22/2025CNTBConnect BiopharmaNorthland CapmkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASBPAspire BiopharmaN/AN/AN/AN/A($2.17) per shareN/ACNTBConnect Biopharma$26.03M3.48N/AN/A$1.67 per share0.97OVIDOvid Therapeutics$570K149.08N/AN/A$0.96 per share1.24VXRTVaxart$47.40M1.88N/AN/A$0.26 per share1.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASBPAspire Biopharma-$12.54MN/A0.00∞N/AN/AN/A-737.96%N/ACNTBConnect Biopharma-$15.63MN/A0.00N/AN/AN/AN/AN/AN/AOVIDOvid Therapeutics-$26.43M-$0.53N/AN/AN/A-574.44%-58.87%-43.18%11/11/2025 (Estimated)VXRTVaxart-$66.95M-$0.25N/AN/AN/A-122.63%-91.89%-38.40%11/12/2025 (Estimated)Latest ASBP, VXRT, OVID, and CNTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ASBPAspire BiopharmaN/A-$0.04N/A-$0.04N/AN/A8/13/2025Q2 2025OVIDOvid Therapeutics-$0.16-$0.06+$0.10-$0.06$0.09 million$6.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASBPAspire BiopharmaN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASBPAspire BiopharmaN/A0.090.09CNTBConnect Biopharma0.017.247.24OVIDOvid Therapeutics0.234.724.72VXRTVaxartN/A0.640.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASBPAspire Biopharma19.17%CNTBConnect Biopharma58.72%OVIDOvid Therapeutics72.24%VXRTVaxart18.05%Insider OwnershipCompanyInsider OwnershipASBPAspire Biopharma48.00%CNTBConnect Biopharma22.60%OVIDOvid Therapeutics13.10%VXRTVaxart2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASBPAspire BiopharmaN/A49.53 million25.75 millionN/ACNTBConnect Biopharma11055.72 million43.13 millionOptionableOVIDOvid Therapeutics6071.11 million61.80 millionOptionableVXRTVaxart120228.94 million222.37 millionOptionableASBP, VXRT, OVID, and CNTB HeadlinesRecent News About These CompaniesVaxart (NASDAQ:VXRT) Shares Pass Below 200 Day Moving Average - Should You Sell?September 14 at 4:26 AM | marketbeat.comConcerned Vaxart Stockholders Condemn Board’s Decision to Adjourn Reverse Stock Split Vote at Special MeetingSeptember 10, 2025 | markets.businessinsider.comVaxart Reports Promising Phase 1 Results for Second-Generation Norovirus Vaccine Inducing Increased Fecal IgA ResponseSeptember 10, 2025 | quiverquant.comQVaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine CandidateSeptember 10, 2025 | globenewswire.comConcerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special MeetingSeptember 10, 2025 | globenewswire.comVaxart Announces Adjournment of Special Meeting of StockholdersSeptember 8, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - What's Next?September 6, 2025 | marketbeat.comVaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025September 3, 2025 | markets.businessinsider.comVaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of DirectorsSeptember 3, 2025 | markets.businessinsider.comVaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.September 2, 2025 | globenewswire.comConcerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board AccountabilitySeptember 2, 2025 | globenewswire.comVaxart Granted Extension by Nasdaq to Regain ComplianceAugust 29, 2025 | markets.businessinsider.comVaxart (NASDAQ:VXRT) Stock Crosses Below 200-Day Moving Average - Here's WhyAugust 29, 2025 | marketbeat.comVaxart Discusses Reverse Stock Split ProposalAugust 21, 2025 | tipranks.comConcerned Vaxart Stockholders Unite to Oppose Vaxart’s Latest Reverse Stock Split and Defend Stockholder RightsAugust 21, 2025 | markets.businessinsider.comConcerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder RightsAugust 21, 2025 | globenewswire.comVaxart, Inc. (VXRT) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comVAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue EstimatesAugust 13, 2025 | zacks.comUS orders Vaxart to stop COVID-19 trial amid mRNA wind downAugust 13, 2025 | reuters.comVaxart, Inc. Stock (VXRT) Opinions on Reverse Stock Split ProposalJuly 31, 2025 | quiverquant.comQVaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on NasdaqJuly 24, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGrab Holdings: Get a Grip Now—Explosive Upside Brewing By Thomas Hughes | August 18, 2025Small Cap, Big Potential: 3 Tech Disruptors You Should Know AboutBy Nathan Reiff | August 22, 2025Is It Too Late to Jump on the Nuclear Bandwagon? By Jordan Chussler | August 25, 2025AI Exposure Without the Hype: 3 ETFs That Offer Smarter AI BetsBy Nathan Reiff | August 25, 2025What August Labor Data Means for the S&P 500 in SeptemberBy Thomas Hughes | September 8, 2025ASBP, VXRT, OVID, and CNTB Company DescriptionsAspire Biopharma NASDAQ:ASBP$0.45 +0.01 (+1.44%) As of 02:52 PM EasternAspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.Connect Biopharma NASDAQ:CNTB$1.64 +0.04 (+2.17%) As of 03:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Ovid Therapeutics NASDAQ:OVID$1.22 +0.08 (+6.58%) As of 03:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Vaxart NASDAQ:VXRT$0.38 -0.01 (-2.56%) As of 02:45 PM EasternVaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
